In this single-assignment , unblinded study , we treated fifty-six menopausal women with HCV-G@ , @ % F@-F@ , and previous PEG - / RBV failure ( @ % null , @ % non-responder , and @ % relapser ) with @ wk lead-in with PEG-IFN@b / RBV followed by PEG-IFN@b / RBV+B oceprevir for @ wk , with an additional @ wk of PEG-IFN -- @b/RBV if patients were HCV-RNA-positive by week @ .